Explore Canaritech's innovative services and dedicated team in Santa Fe, Nuevo Mexico. Learn what drives our company and how we deliver exceptional solutions. Join us on a journey of technology and trust.
Canaritech: Advancing Clinical Research in Latin America
As a leading Contract Research Organization we play a crucial supportive role in the broader drug development pipeline by facilitating the efficient advancement of promising compounds emerging from drug discovery into rigorous clinical validation, helping biotechnology and pharmaceutical partners accelerate innovative therapies toward regulatory approval and market access in the region.
Drug Discovery
Target Identification & Validation
Target Identification and Validation is the foundational stage in drug discovery, where potential biological targets -typically proteins, genes, or pathways linked to a disease.
Hit Identification
Is the stage in drug discovery that follows target validation, where large libraries of chemical compounds are screened to identify initial "hits".
Lead Optimization
Is a critical stage in drug discovery that follows the hit to-lead phase, involving iterative chemical modifications to promising lead compounds to enhance their potency, selectivity, and pharmacokinetic properties.
Gallery
"Canaritech: Bridging drug discovery to clinical reality"
With regional expertise
Team
Francisco Javier Pérez Davó
Is a Mexican lawyer and business executive based in Santa Fe NM and Mexico City, currently serving as CEO of Canaritech, a Contract Research Organization (CRO) founded in 2024 that specializes in clinical trials across Latin America including regulatory consulting, trial management, and decentralized studies in countries such as Mexico, Peru, Chile, Colombia and Argentina. With a background in law and extensive professional experience, Pérez Davó brings expertise in operational and financial consulting to his leadership role, driving Canaritech mission to innovate clinical research and improve access to advanced therapies in the region.